20250630_INAF_Ringkasan Risalah//Risalah RUPS_31909768_lamp2.pdf

 The Company also uploaded the Meeting Agenda Materials on the Company's website
 (https://www.indofarma.id) on June 05, 2025

C. There are no additional proposals for Meeting Agendas from the Company's Shareholders until the
   deadline as stipulated in Article 23 paragraph (6) letter a of the Company's Articles of Association,
   namely until 7 (seven) days before the date of the Meeting Invitation which was announced on May
   27, 2025.

D. The meeting was attended by all members of the Board of Commissioners and members of the Board
   of Directors and Shareholders of the Company, namely:

  BOARD OF COMMISSIONERS
  Independent Commissioner             : Mr. TEDDY WIBISANA;

  Acting President Commissioner/        : Mr. DIDI AGUS MINTADI.
  Commissioner

  BOARD OF DIRECTORS
  Acting President Director/
  Operational Director                 : Mr. ANDI PRAZOS.

  as well as Shareholders and proxies of Shareholders who were present physically or electronically
  through eASY.KSEI who all own 2,925,939,900 shares including Series A Dwiwarna shares or constitute
  94.4074656% of the total number of shares with valid voting rights that have been issued by the
  Company up to the day of the Meeting, namely 3,099,267,500 shares consisting of:
  - 1 Series A Dwiwarna share; and
  - 3,099,267,499 Series B shares
  with due observance of the Company's Shareholders List as of June 2, 2025 until 16:00 Western
  Indonesia Time.

  E. The meeting was chaired by the Company's Commissioner, Mr. Dr. DIDI AGUS MINTADI based on the
     letter of the Board of Commissioners dated June 3, 2025 Number S-21/DK-INAF/VI/2025.

  F. The Meeting was held with the following Agenda:

    1. Approval of the Annual Report and Ratification of the Company's Consolidated Financial
        Statements, Approval of the Board of Commissioners' Supervisory Task Report and Ratification of
        the Financial Statements of the Micro and Small Business Funding Program (PUMK) for the 2024
        Financial Year, as well as Granting of Full Settlement and Release of Liability (volledig acquit et de
        charge) to the Board of Directors for the Company's Management Actions and the Board of
        Commissioners for the Company's Supervisory Actions that have been carried out during the 2024
        Financial Year.
    2. Approval of the Use of the Company's Net Profit for the 2024 Financial Year.
    3. Determination of Salaries/Honorariums including Facilities and Allowances for the 2025 Financial
        Year, as well as Tantiem/Performance Incentives/Special Incentives for Performance in 2024 for
        the Company's Board of Directors and Board of Commissioners.



                                                    2

   4. Approval of the Appointment of a Public Accountant and/or Public Accounting Firm (KAP) to Audit
       the Company's Consolidated Financial Statements for the 2025 Financial Year and the Financial
       Statements of the Micro and Small Business Funding Program (PUMK) for the 2025 Financial Year.
   5. Changes to the Company's Management.

G. In the Meeting, the presentation of the Company's general condition was delivered by the Chairperson
    of the Meeting, namely Mr. Dr. DIDI AGUS MINTADI.

   In each Agenda of the Meeting, the opportunity was given to the Company's shareholders and proxies
   of shareholders who were present physically or electronically to submit questions and/or opinions.
   In the First, Third, Fourth, and Fifth Agendas of the Meeting, there were no shareholders and proxies
   of shareholders of the Company who were present physically or electronically who submitted
   questions and/or opinions. In the Second Agenda of the Meeting, there was 1 (one) Shareholder who
   submitted a question electronically.

H. That the decision-making mechanism in the Meeting is carried out through deliberation to reach
   consensus in accordance with Article 40 with due regard to Article 28 of POJK No. 15/2020. In the
   event that deliberation for consensus is not reached, then the decision is taken through voting. The
   voting mechanism is carried out openly calculated from the votes legally cast from the Meeting and
   through eASY.KSEI.

   That in the Meeting a decision has been taken as stated in the deed "Minutes of the Second Annual
   General Meeting of Shareholders for the 2024 Financial Year of PT INDONESIA FARMA Tbk
   abbreviated as PT INDOFARMA Tbk" dated 25 June 2025 Number 29 whose minutes of the deed were
   made by Notary Utiek Rochmuliati Abdurachman, SH., MLI., MKn. which in essence are as follows:


In the First Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at
the Meeting, none voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the rest,
2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900
shares or 100% of the total number of votes cast at the Meeting decided:

1. Approve the Company's Annual Report including the Board of Commissioners' Supervisory Task
   Report for the Financial Year ending on December 31, 2024.
2. Ratify:
   a) The Company's Consolidated Financial Statements for the Financial Year 2024 ending on
      December 31, 2024 which have been audited by the Public Accounting Firm HELIANTONO and
      Partners in accordance with its report Number 00386/2.0459/AU.1/04/0916-1/1/IV/2025 dated
      April 17, 2025 with the opinion “Fair with Exceptions” in connection with the failure to obtain
      sufficient and appropriate audit evidence on the recoverable value of consolidated fixed assets


                                                 3

     and inventories in which there are assets of a subsidiary, namely PT IGM, which on February 10,
     2025 was declared bankrupt with all its legal consequences by the Central Jakarta District Court;
   b) Financial Report of the Micro and Small Business Funding Program for the 2024 Financial Year
       ending on December 31, 2024 which is part of the Social and Environmental Responsibility
       Report as audited by the Public Accounting Firm HELIANTONO and Partners according to its
       report Number 00683/2.0459/AU.2/04/0916-1/1/IV/2025 dated April 17, 2025 with the
       opinion "fair in all material respects",
  3. The Board of Directors and Board of Commissioners are requested to fully resolve the matters
     that caused the recording of losses in the Company's Consolidated Financial Statements for the
     2024 Financial Year and to consistently carry out their duties and functions carefully and
     prudently to optimize all resources owned by PT Indofarma Tbk in order to fully resolve the
     restructuring of PT Indofarma Tbk, in order to maintain the continuity of the Company's
     business.
  4. With the approval of the Company's Annual Report including the Board of Commissioners'
     Supervisory Task Report, and the ratification of the Company's Consolidated Financial
     Statements and the Financial Statements of the Micro and Small Business Funding Program
     (PUMK), for the 2024 Financial Year ending on December 31, 2024, the General Meeting of
     Shareholders grants release and discharge (acquit et de charge) to all members of the Board of
     Directors for their management actions and to all members of the Board of Commissioners for
     their supervisory actions carried out during the 2024 Financial Year ending on December 31,
     2024, except for the cause of the opinion “Fair with Exceptions”, as long as such actions do not
     constitute a criminal act and/or violate the provisions of applicable laws and legal procedures,
     and are reflected in the Company's report books.


In the Second Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at
the Meeting, none voted Disagree; of 425,907,700 shares or 14.5562696% voted Abstain; while the rest,
2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation for consensus, namely 2,925,939,900 shares or
100% of the total number of votes cast at the Meeting decided:

Approved that there is no determination of the Use of the Company's Net Profit because the Company
experienced a net loss in the 2024 Financial Year.


In the Third Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented both physically and electronically at
the Meeting, 0 shares or 0% voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while
the rest, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.



                                                 4

In accordance with the provisions in the Meeting Rules of Procedure, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900
shares or 100% of the total number of votes cast at the Meeting decided:

Approve the Determination of Tantiem/Performance Incentives/Special Incentives for the 2024
Financial Year, Salaries for the Board of Directors and Honorariums for the Board of Commissioners
along with other facilities and allowances for the Year 2025, will be determined separately by the
Series A Dwiwarna Shareholders.


In the Fourth Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at
the Meeting, 0 shares or 0% voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while
the rest, amounting to 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share
voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation for consensus, namely 2,925,939,900 shares or
100% of the total number of votes issued at the Meeting decided:

1. Granting authority to the Board of Commissioners after first obtaining written approval from the
   Most Series B Shareholders to appoint a Public Accounting Firm to carry out an audit of the
   Company's Consolidated Financial Statements and the Financial Statements for the
   Implementation of the Micro and Small Business Funding Program (PUMK) for the 2025 Financial
   Year, including other reports in 2025.
2. Delegating authority to the Company's Board of Commissioners to determine the amount of fees
   for audit services of the Public Accounting Firm that has been approved in decision number 1)
   above and the addition of the scope of work required and other requirements that are reasonable
   for the Public Accounting Firm.
3. Delegating authority to the Board of Commissioners after first obtaining written approval from the
   Most Series B Shareholders to determine:
   a. A replacement Public Accounting Firm if the appointed Public Accounting Firm cannot continue
      or carry out its duties for any reason; and
   b. Conditions, requirements for appointment and honorarium of the replacement Public
      Accounting Firm.


In the Fifth Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at
the Meeting, none voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the
remainder, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted
Agree.

                                                 5

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote
(abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900
shares or 100% of the total number of votes cast in the Meeting decided:

1. Approve the honorable dismissal of the members of the Board of Directors and Board of
    Commissioners of PT INDOFARMA Tbk, as follows:
    a. Mrs. YELIANDRIANI as President Director;
    b. Mr. TEDDY WIBISANA as Independent Commissioner;
    c. Mr. Dr. DIDI AGUS MINTADI as Commissioner.
    effective as of the closing of this year's Annual GMS, with gratitude for the contribution of energy
    and thoughts given during their respective terms as members of the Board of Directors and Board
    of Commissioners of PT INDOFARMA Tbk.
2. Approve the appointment of the names below as members of the Board of Directors and Board of
    Commissioners of PT INDOFARMA Tbk, as follows:
    a. Mr. SAHAT SIHOMBING as President Director;
    b. Mr. Dr. DIDI AGUS MINTADI as Commissioner for the second term.
3. The term of office of the members of the Board of Directors and Board of Commissioners appointed
    as referred to in number 2, in accordance with the provisions of the Company's Articles of
    Association, taking into account the laws and regulations in the Capital Market sector and without
    prejudice to the right of the GMS to dismiss at any time.
4. With the dismissal and appointment of members of the Board of Directors and Board of
    Commissioners as referred to in numbers 1 and 2 above, the composition of the membership of
    the Board of Commissioners and Board of Directors of PT INDOFARMA Tbk is as follows:

   BOARD OF COMMISSIONERS
   President Commissioner           :-
   Commissioner                     : Mr. DIDI AGUS MINTADI.
   BOARD OF DIRECTORS
   President Director               : Mr. SAHAT SIHOMBING;
   Operational Director             : Mr. ANDI PRAZOS



                                       Jakarta, June 30, 2025
                                 Board of Directors of the Company




                                                 6